These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23212356)

  • 21. Successful Surgical Management of Retinopathy of Prematurity Showing Rapid Progression despite Extensive Retinal Photocoagulation.
    Gadkari SS; Kulkarni SR; Kamdar RR; Deshpande M
    Middle East Afr J Ophthalmol; 2015; 22(3):393-5. PubMed ID: 26180484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights in diagnosis and treatment for Retinopathy of Prematurity.
    Cernichiaro-Espinosa LA; Olguin-Manriquez FJ; Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
    Int Ophthalmol; 2016 Oct; 36(5):751-60. PubMed ID: 26767656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
    Eldweik L; Mantagos IS
    Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
    Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
    Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
    [No Abstract]   [Full Text] [Related]  

  • 27. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SAFER-ROP: Updated Protocol for Anti-VEGF Injections for Retinopathy of Prematurity.
    Beck KD; Rahman EZ; Ells A; Mireskandari K; Berrocal AM; Harper CA
    Ophthalmic Surg Lasers Imaging Retina; 2020 Jul; 51(7):402-406. PubMed ID: 32706898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.
    Seery CW; Betesh S; Guo S; Zarbin MA; Bhagat N; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2020 Nov; 57(6):351-362. PubMed ID: 33211892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
    Cheng HC; Lee SM; Hsieh YT; Lin PK
    Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comparison of Respiratory Outcomes after Treating Retinopathy of Prematurity with Laser Photocoagulation or Intravitreal Bevacizumab.
    Barry GP; Tauber KA; Greenberg S; Lajoie J; Afroze F; Oechsner H; Finucane E; Binenbaum G
    Ophthalmol Retina; 2020 Dec; 4(12):1202-1208. PubMed ID: 32512055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 33. Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation.
    Chen YC; Chen SN
    Br J Ophthalmol; 2020 May; 104(5):691-696. PubMed ID: 31420328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection.
    Bhatt AR; Paul Chan RV; Reynolds JD; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2019 Mar; 56(2):68-70. PubMed ID: 30889257
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of retinopathy of prematurity.
    Fleck BW
    Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F454-6. PubMed ID: 23813885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.
    Shah PK; Subramanian P; Venkatapathy N; Chan RVP; Chiang MF; Campbell JP
    J AAPOS; 2019 Oct; 23(5):264.e1-264.e4. PubMed ID: 31521847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.
    Abri Aghdam K; Khadamy J; Falavarjani KG; Tsui I
    J AAPOS; 2016 Dec; 20(6):539-540.e3. PubMed ID: 27810419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging treatments for retinopathy of prematurity.
    Mantagos IS; Vanderveen DK; Smith LE
    Semin Ophthalmol; 2009; 24(2):82-6. PubMed ID: 19373691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.